The Zurich-based startup offering a forecasting tool for the foodservice industry has made changes in its leadership. Former CTO Roman Lickel is now the company’s Managing Director. Roman takes over the role from Simon Michel, with whom he built Prognolite. “The last few years have been an incredibly intense and beautiful time. Although I believe in success more than ever, I see that Prognolite can be better led by my co-founder Roman together with Nico with the somewhat changed focus. As a shareholder, however, I will remain closely connected to Prognolite,” says Simon.
For its platform that allows over 40,000 tenants to rent everyday objects, Sharely has welcomed Lucie Rein as its new CEO to further grow Sharely as a leading sharing platform. Lucie brings several years of experience having worked at companies such as the startups Farmy and Too Good To Go and leading global companies Barilla and Nestlé, Danone and Ikea. Sharely has seen remarkable growth since its foundat
Kinarus further strengthens its leadership with two reputed industry experts
EQS Group-News: Kinarus AG / Key word(s): Personnel/Private Equity
26.04.2021 / 07:01
Hari Kumar, former CEO of Adheron Therapeutics, Inc. appointed Chairman of the Board of Directors
Thierry Fumeaux, MD, former member of Swiss National Covid Taskforce, joined Kinarus as new Chief Medical Officer
Basel, Switzerland, April 26, 2021. Kinarus AG, a Swiss clinical-stage biopharmaceutical company and owner of KIN001, a differentiated therapeutic candidate for the treatment of multiple diseases with high unmet need, announced today the appointment of Hari Kumar as Chairman of the Board of Directors and Thierry Fumeaux as Chief Medical Officer.
EQS-News: Kinarus further strengthens its leadership with two reputed industry experts
Kinarus AG,
Dr. Hari Kumar s long career took him from Roche to Eisai Ltd where he served as European Marketing Director. He returned to Roche as Global Head of Transplant Immunosuppressives. He subsequently moved to Amira Pharmaceuticals Inc. in 2007 as Chief Business Officer before becoming Chief Executive Officer of Adheron Therapeutics Inc.? In his career, Dr. Kumar oversaw the launch of the immunosuppressive, CellCept(R), the Alzheimer s drug, Aricept(R) and the gastric ulcer drug, Aciphex(R). At Amira, Dr. Kumar led the process that resulted in its acquisition by Bristol Myers Squibb in 2011. He also navigated the acquisition of Adheron Therapeutics by Roche, in his role as CEO/ Board member. These transactions have delivered over a billion dollars in returns to investors.